



## **Mattia Rediti**

### **Contact**

Mattia Rediti

## Publications (3)

Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. *JAMA Oncol* 2024

Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. *Clin Cancer Res* 2021

Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur Urol Oncol* 2019

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)